证券研究报告 | 2026年02月01日 公募 REITs 周报（第 52 期） 指数震荡上行，首批商业不动产 REITs 已申报 主要结论：本周 REITs 震荡上行，表现强于主要股债指数。中证 REITs 指数 周涨 0.8%，水利、能源、交通 REITs 涨幅领先,前期涨幅较大的数据中心调 整较大。从主要指数周涨跌幅对比来看，中证 REITs>沪深 300>中证全债>中 证转债。截至 2026 年 1 月 30 日，产权类 REITs 股息率比中证红利股股息率 均值低 60BP，经营权类 REITs 内部收益率均值与十年期国债收益率利差为 326BP。首批8单商业不动产REITs申报获上交所受理，意味着我国公募REITs 市场正实现从基础设施领域向商业不动产领域的关键扩容。 中证 REITs 指数周涨跌幅为 0.8%，年初至今涨跌幅为+4.4%。截至 2026 年 1 月 30 日，中证 REITs（收盘）指数收 盘价为 809.56 点，整周 （2026/1/24-2026/1/30）涨跌幅为 0.8%，表现强于中证转债指数 （-2.6%）、中证全债指数（0.0%）和沪深 300 指数（0.1%）。年 ...

本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部 A 股下 跌 0.98%（总市值加权平均），沪深 300 上涨 0.08%，中小板指下跌 3.78%，创业板指下跌 0.09%，生物医药板块整体下跌 3.31%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 3.20%，生物 制品下跌 2.50%，医疗服务下跌 4.15%，医疗器械下跌 3.86%，医药商 业下跌 4.49%，中药下跌 1.94%。医药生物市盈率（TTM）37.27x，处 于近 5 年历史估值的 80.47%分位数。 精锋医疗为领先的手术机器人公司。精锋医疗成立于 2017 年，是中国 首家、全球第二家同时取得多孔腔镜、单孔腔镜及自然腔道三类手术机 器人注册审批的领先企业，2024 年斩获国内手术机器人制造商销量第 一，2026 年 1 月于香港联交所挂牌上市。公司核心管理层具备深厚的 行业经验与国际背景，全球专利布局超 734 项，技术实力雄厚。 精锋医疗构建了覆盖多科室的丰富管线。多孔系列 MP1000 及升级款 已获批多专科应用并实现商业化放量，单孔系列 SP1000 为国内首个 覆盖三大外科的国产单孔机器人，支气管 ...

Report Industry Investment Rating No relevant content provided. Core Viewpoints of the Report - The sustainability of polarized valuations depends on the direction of the equity market. The report presents three scenarios for the equity market and corresponding convertible bond strategies: 1) If the spring rally continues, the Shanghai Composite Index breaks through 4,200, and the market style shifts from small - cap to large - cap, it is recommended to select convertible bonds related to the battery, automotive/robot/intelligent driving, edge - side AI, and innovative drug/CDMO sectors in the growth technology sector; 2) If the broad - based index continues the January oscillation and the small - cap style remains dominant, focus on core targets in popular tracks such as commercial space, AIDC - related gas turbines/liquid cooling, semiconductor equipment and materials, power semiconductors, and chemical industries; 3) If the equity market turns down, it is recommended to reduce positions first and then focus on defensive sectors like banks, power, and pig farming [2][20]. Summary According to Relevant Catalogs Market Focus from January 26 - January 30, 2026 - **Stock Market**: Daily trading volume remained high with rapid sector rotation. The precious metals sector led the gains but had a significant decline on Friday. The A - share oil and gas sector performed well due to the potential conflict risk between the US and Iran. Some previously popular sectors such as commercial space and space photovoltaics had significant pullbacks. Different sectors rose and fell on different days. In terms of industries, most Shenwan primary industries declined, with petroleum and petrochemicals, communications, coal, non - ferrous metals, and agriculture, forestry, animal husbandry, and fishery leading the gains, while national defense and military industry, power equipment, automotive, and computer sectors performing poorly [8][9]. - **Bond Market**: The central bank's open - market operations were mainly net injections, and the money market shifted from tight to loose. Bond market sentiment was generally strong. The 10 - year Treasury bond yield closed at 1.81% on Friday, down 1.86bp from the previous week [9]. - **Convertible Bond Market**: Most convertible bond issues declined. The CSI Convertible Bond Index fell 2.61% for the week, the median price dropped 2.22%, the arithmetic average parity fell 3.70%, and the overall market conversion premium rate increased 1.12% compared to the previous week. The arithmetic average conversion premium rates of convertible bonds in different parity ranges changed, and they were at high percentile values since 2023 [9]. Viewpoints and Strategies from February 2 - February 6, 2026 - After the convertible bond market adjusted with the equity market last week, the sustainability of polarized valuations depends on the equity market's direction. Three scenarios and corresponding strategies are proposed as mentioned in the core viewpoints [2][20]. Valuation Overview - As of January 30, 2026, the average conversion premium rates of equity - biased convertible bonds in different parity ranges were at high percentile values since 2010 and 2021. The average YTM of debt - biased convertible bonds with a parity below 70 yuan was at a low percentile value. The average implied volatility of all convertible bonds and the difference between the convertible bond implied volatility and the long - term actual volatility of the underlying stocks were at high percentile values [21]. Primary Market Tracking - **Last Week (January 26 - January 30, 2026)**: No convertible bonds were announced for issuance. Lianrui Convertible Bond and Naipu Convertible Bond 02 were listed. Lianrui Convertible Bond has a scale of 695 million yuan, and Naipu Convertible Bond 02 has a scale of 450 million yuan [28][29]. - **Future Outlook**: No convertible bonds are announced for issuance or listing in the next week (February 2 - February 6, 2026). As of now, there are 100 convertible bonds waiting to be issued, with a total scale of 155.9 billion yuan, of which 8 have been approved for registration, with a total scale of 6.16 billion yuan [30][31].

Group 1: Report Overview - The report conducts a weekly tracking of private exchangeable bonds (private EB) from January 26 to January 30, 2026 [1]. Group 2: New Project Information - Shanghai Qichen Enterprise Management Co., Ltd.'s 2026 private placement of exchangeable corporate bonds for professional investors has been accepted by the exchange, with an intended issuance scale of 500 million yuan and the underlying stock being GCL Integrated Energy Co., Ltd. (002015.SZ). The lead underwriter is Soochow Securities, and the exchange update date is January 28, 2026 [1]. Group 3: Project Status Summary | Bond Name | Lead Underwriter | Scale (100 million yuan) | Underlying Stock | Project Status | Update Date | | --- | --- | --- | --- | --- | --- | | Fuda Holding Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Zhongde Securities | 12 | Fuda Co., Ltd. | Approved | 2026/1/5 | | Nanshan Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Jinyuan United Securities | 30 | Nanshan Aluminum Co., Ltd. | Approved | 2025/12/25 | | Sichuan Jiuzhou Investment Holding Group Co., Ltd. 2025 private placement of science - and - technology innovation exchangeable corporate bonds for professional investors | CITIC Securities | 10 | Sichuan Jiuzhou Electric Appliance Co., Ltd. | Approved | 2025/12/5 | | Origen Technology Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | CITIC Construction Securities | 3.5 | Yongxin Co., Ltd. | Approved | 2025/12/5 | | New Hope Group Co., Ltd. 2025 private placement of science - and - technology innovation exchangeable corporate bonds for professional investors | CICC | 45 | New Hope Group Co., Ltd. | Approved | 2025/11/27 | | Hangzhou Iron & Steel Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Zheshang Securities | 10 | Hangzhou Iron & Steel Co., Ltd. | Approved | 2025/11/7 | | Guangdong Guangxin Holdings Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | CITIC Securities | 30 | Shengyi Technology Co., Ltd. | Approved | 2025/10/30 | | Fujian State - owned Assets Management Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Guoxin Securities | 2 | Fuzhou Focal Optics Co., Ltd. | Approved | 2025/10/29 | | Beijing Harmony Hengyuan Technology Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Hongta Securities | 6 | Sichuan Shuangma Cement Co., Ltd. | Approved | 2025/7/18 | | Shudao Investment Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | CITIC Securities, Hongxin Securities | 50 | Sichuan Road & Bridge Co., Ltd. | Approved | 2025/4/30 | | China Pingmei Shenma Group Co., Ltd. 2024 private placement of exchangeable corporate bonds for professional investors | Ping An Securities | 10 | Shenma Industrial Co., Ltd., Pingdingshan Tianan Coal Mining Co., Ltd. | Approved | 2025/4/29 | | Wanan Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Zheshang Securities | 6 | Wanan Technology Co., Ltd. | Approved | 2025/4/25 | | Inner Mongolia Huolinhe Coal Industry Group Co., Ltd. 2024 private placement of carbon - neutral green exchangeable corporate bonds | Ping An Securities | 5.4 | Inner Mongolia Electric Power Investment Energy Co., Ltd. | Approved | 2025/4/25 | | Huabang Life Science Co., Ltd. 2026 private placement of science - and - technology innovation exchangeable corporate bonds for professional investors | Huatai United Securities, Southwest Securities | 10 | Kaisheng New Materials Co., Ltd. | Feedback received | 2026/1/23 | | Hainan农垦 Investment Holding Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | CITIC Securities | 21 | Hainan Rubber Industry Group Co., Ltd. | Feedback received | 2025/12/8 | | Strait Innovation Internet Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | Dongguan Securities | 3 | Fengzhushou Co., Ltd. | Feedback received | 2025/11/13 | | Guangzhou Intelligent Equipment Industry Group Co., Ltd. 2025 private placement of exchangeable corporate bonds for professional investors | CICC | 10 | Guangri Co., Ltd. | Feedback received | 2025/9/26 | | Shanghai Qichen Enterprise Management Co., Ltd. 2026 private placement of exchangeable corporate bonds for professional investors | Soochow Securities | 5 | GCL Integrated Energy Co., Ltd. | Accepted | 2026/1/28 | | Northern Lingyun Industry Group Co., Ltd. 2026 private placement of exchangeable corporate bonds for professional investors | CITIC Construction Securities | 5 | Lingyun Industry Co., Ltd. | Accepted | 2026/1/28 | | Shenzhen Huaqiang Group Co., Ltd. 2026 private placement of exchangeable corporate bonds for professional investors | Jinyuan United Securities | 24 | Shenzhen Huaqiang Co., Ltd. | Accepted | 2026/1/22 | [3] Group 4: Related Research Reports - "Private Exchangeable Bond Tracking - Private EB Weekly Tracking (20260119 - 20260123)" - 2026 - 01 - 25 - "Private Exchangeable Bond Tracking - Private EB Weekly Tracking (20260112 - 20260116)" - 2026 - 01 - 18 - "Private Exchangeable Bond Tracking - Private EB Weekly Tracking (20260105 - 20260109)" - 2026 - 01 - 11 - "Private Exchangeable Bond Tracking - Private EB Weekly Tracking (20251229 - 20251231)" - 2026 - 01 - 04 - "Private Exchangeable Bond Tracking - Private EB Weekly Tracking (20251222 - 20251226)" - 2025 - 12 - 29 [4]

证券研究报告 | 2026年02月01日 港股市场速览 优于大市 大盘风格传统行业估值拉升 股价表现：大盘风格传统行业带动市场显著上涨 本周，恒生指数+2.4%，恒生综指+1.8%。风格方面，大盘（恒生大型股+2.2%） ＞中盘（恒生中型股+0.3%）＞小盘（恒生小型股-1.2%）。 主要概念指数分化。上涨的主要有恒生高股息（+4.2%）；下跌的主要有恒 生生物科技（-2.5%）。 国信海外选股策略分化。上涨的主要有红利贵族 50（+2.8%）；下跌的主要 有自由现金流 30（-1.7%）。 16 个行业上涨，14 个行业下跌。上涨的主要有：石油石化（+8.7%）、综合 （+6.3%）、建材（+6.3%）、房地产（+5.8%）、非银行金融（+5.8%）；下 跌的主要有：国防军工（-4.5%）、电力设备及新能源（-3.4%）、医药（-2.8%）、 钢铁（-2.3%）、汽车（-2.2%）。 估值水平：红利估值拉升，多数概念下降 本周，恒生指数估值（动态预期 12 个月正数市盈率，后同）+1.8%至 12.0x； 恒生综指估值+1.2%至 12.0x。 主要概念指数估值普遍下降。上升幅度较大的是恒生高股息（+4.2 ...

Market Performance - S&P 500 increased by 0.3% while Nasdaq decreased by 0.2% this week[1] - Small-cap stocks led the decline with Russell 2000 value down by 1.0% and Russell 2000 growth down by 3.1%[1] - Key sectors showing gains include telecommunications (+9.0%) and technology hardware (+4.6%) while software and services fell by 6.9%[1] Fund Flows - Estimated fund flow for S&P 500 components was -$84.1 million this week, a significant drop from +$5.6 million last week[2] - Major inflows were seen in technology hardware (+$40.3 million) and media and entertainment (+$39.5 million) while software and services experienced outflows of -$106.0 million[2] Earnings Forecast - S&P 500's forward 12-month EPS expectation increased by 0.8% this week, up from 0.2% last week[3] - Notable upward revisions were in technology hardware (+5.6%) and automotive (+3.2%) sectors, while energy saw a downward revision of -2.7%[3] Risk Factors - Economic fundamentals, international political uncertainties, U.S. fiscal policy, and Federal Reserve monetary policy present significant risks[3]

证券研究报告 | 2026年02月01日 港股市场速览 优于大市 大盘风格传统行业估值拉升 股价表现：大盘风格传统行业带动市场显著上涨 本周，恒生指数+2.4%，恒生综指+1.8%。风格方面，大盘（恒生大型股+2.2%） ＞中盘（恒生中型股+0.3%）＞小盘（恒生小型股-1.2%）。 主要概念指数分化。上涨的主要有恒生高股息（+4.2%）；下跌的主要有恒 生生物科技（-2.5%）。 国信海外选股策略分化。上涨的主要有红利贵族 50（+2.8%）；下跌的主要 有自由现金流 30（-1.7%）。 16 个行业上涨，14 个行业下跌。上涨的主要有：石油石化（+8.7%）、综合 （+6.3%）、建材（+6.3%）、房地产（+5.8%）、非银行金融（+5.8%）；下 跌的主要有：国防军工（-4.5%）、电力设备及新能源（-3.4%）、医药（-2.8%）、 钢铁（-2.3%）、汽车（-2.2%）。 估值水平：红利估值拉升，多数概念下降 本周，恒生指数估值（动态预期 12 个月正数市盈率，后同）+1.8%至 12.0x； 恒生综指估值+1.2%至 12.0x。 主要概念指数估值普遍下降。上升幅度较大的是恒生高股息（+4.2 ...

Market Performance - S&P 500 increased by 0.3% while Nasdaq decreased by 0.2% this week[1] - Small-cap stocks led the decline with Russell 2000 value down by 1.0% and Russell 2000 growth down by 3.1%[1] - 13 sectors saw gains, while 10 sectors experienced losses, with telecommunications leading at +9.0%[1] Fund Flows - Estimated fund flow for S&P 500 components was -$84.1 million this week, down from +$5.6 million last week[2] - Major inflows were seen in technology hardware (+$40.3 million) and media & entertainment (+$39.5 million)[2] - Significant outflows occurred in software & services (-$106.0 million) and healthcare equipment & services (-$57.7 million)[2] Earnings Forecast - S&P 500's forward 12-month EPS expectation increased by 0.8% this week, up from 0.2% last week[3] - 21 sectors had upward revisions, with technology hardware & equipment seeing the largest increase at +5.6%[3] - Energy sector saw a downward revision of -2.7%[3] Risks - Economic fundamentals, international political situations, U.S. fiscal policies, and Federal Reserve monetary policies present uncertainties[3]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The surgical robot market is expected to grow significantly, driven by technological innovation, clinical demand, and policy benefits, particularly in China where the penetration rate is projected to increase from 0.7% in 2024 to 3.0% by 2033 [20][29] - Jingfeng Medical is a leading surgical robot company in China, having achieved significant milestones including the first domestic sales ranking in 2024 and a successful listing on the Hong Kong Stock Exchange in January 2026 [1][10] - The company has a robust pipeline of products across multiple specialties, with its multi-port and single-port surgical robots already commercialized and showing strong sales growth [2][34] Summary by Sections Market Performance - The overall pharmaceutical sector underperformed the market, with a decline of 3.31% in the biopharmaceutical sector, while the A-share market saw an average decline of 0.98% [1] - The TTM price-to-earnings ratio for the biopharmaceutical sector stands at 37.27x, which is at the 80.47th percentile of the past five years [1] Company Overview - Jingfeng Medical was established in 2017 and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [10] - The company has over 734 global patents, showcasing its strong technological capabilities and commitment to innovation [35] Product Pipeline - The company has developed a diverse product line, including the MP1000 multi-port robot and the SP1000 single-port robot, which are approved for various surgical applications [2][10] - The CP1000 bronchoscopic robot is an innovative product aimed at non-invasive diagnosis and treatment of lung diseases, with significant clinical advantages [31][34] Financial Projections - Jingfeng Medical's revenue for the first half of 2025 reached 149 million RMB, a year-on-year increase of 394%, with surgical robot sales accounting for 92.9% of total revenue [34] - The company is expected to continue its growth trajectory with increasing overseas orders and expanding market presence [35] Competitive Landscape - The multi-port surgical robot market is currently dominated by Intuitive Surgical, which holds an 83% market share, while domestic competitors are rapidly emerging [26] - The single-port robot market is still in its early stages, with Jingfeng Medical holding a first-mover advantage in China [28]

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The small nucleic acid drug market is experiencing robust growth, transitioning from technology validation to accelerated commercialization, with a global market size increasing from $2.7 billion in 2019 to $4.6 billion in 2023, and projected to reach $45.7 billion by 2033, reflecting a CAGR of 26.08% [2][39] - The small nucleic acid CXO sector is benefiting from technological breakthroughs and commercialization acceleration, establishing a comprehensive CRDMO service system [2] - Key players in the small nucleic acid field include CROs with core technologies and rich project experience, such as Chengdu XianDai and Kanglong Chemical, and CDMOs with leading production capabilities like WuXi AppTec and Kailai Ying [2] Summary by Sections 1. Small Nucleic Acid Drugs - Small nucleic acid drugs encompass various types, including ASO, siRNA, and aptamers, which target gene expression for disease treatment [11][12] - These drugs offer advantages such as shorter development cycles, broad therapeutic areas, sustained efficacy, and higher success rates compared to traditional drugs [15][16] 2. Market Expansion and BD Activity - The small nucleic acid market is expanding, with significant BD transactions occurring, including a $9 billion collaboration between Wobang Pharmaceutical and Novartis, and a $2 billion platform authorization between Rebio and Boehringer Ingelheim [48] - Domestic companies are actively developing drugs targeting hyperlipidemia, hypertension, and hepatitis B, with notable progress in clinical stages [45][47] 3. CXO Empowerment in Small Nucleic Acid R&D - The CXO industry is crucial for supporting the R&D and production of small nucleic acid drugs, with a focus on enhancing delivery technologies and chemical modifications to improve drug stability and efficacy [22][26]